IMS helps customers determine how to best allocate resources across their portfolios to maximize performance at every stage of the product lifecycle. 

Our data and applications have always been at the core of Portfolio Optimization ... from global overviews to regional and national surveys … from sales volume and market share to prescribing trends by product, company, geography and distribution channel. 

Our Portfolio Optimization offerings support decision-makers in key areas that include:

• Market Opportunity Assessment
• Strategic Planning
• New Business Development
• Market Analysis

Our prescription audits, the industry gold standard, tell customers what physicians are prescribing – and what pharmacists are dispensing – in core markets throughout the world.  Sales audits in more than 100 countries track pharmaceutical product sales through retail and hospital pharmacies. And medical audits, available in more than 45 countries, describe both the occurrence and treatment of diseases, enabling IMS to recommend the best R&D investments based on projected future therapy choices by physicians.

We draw on these and other information assets to design offerings that support the challenge of optimizing pharma product portfolios.

Sometimes, simple questions are the most difficult to answer – and the most important. What products to license? Which therapy classes to enter? Which drugs get the marketing money and which do not? How will our client’s current portfolio perform over the next 3-5 years?  To get the answers, IMS creates tailored solutions combining the power of our data and applications with our team’s expertise.

Whether it’s in-depth business intelligence, analysis, or forecasting, IMS offerings provide pharma customers with the facts, interpretations and guidance they need to make the best portfolio-optimization decisions.

	To learn more about how IMS can help your company, contact us. For regional contact information, click here.

email this page     print this page